Top Markets
Coin of the day
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc.

AZRX
Classifica tra le azioni #35193
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12... AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).
Prezzo delle azioni
$3.45
Ultima sincronizzazione: 2021-09-21
Capitalizzazione di mercato
$4.29M
Variazione (1 giorno)
2.07%
Variazione (1 anno)
0.00%
Paese
US
Scambia AzurRx BioPharma, Inc. (AZRX)

Categoria

Storico del rendimento da dividendi per AzurRx BioPharma, Inc. (AZRX)
Il rendimento da dividendi (TTM) di AzurRx BioPharma, Inc. (simbolo azionario: AZRX) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per AzurRx BioPharma, Inc. (AZRX) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.48%
BE